[CAS NO. 64-77-7]  Tolbutamide (HLS 831)

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [64-77-7]

Catalog
SLK-S2443
Brand
Selleck
CAS
64-77-7

DESCRIPTION [64-77-7]

Overview

MDLMFCD00027169
Molecular Weight270.35
Molecular FormulaC12H18N2O3S
SMILESS(NC(NCCCC)=O)(=O)(=O)C1=CC=C(C)C=C1

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

1 mg5 mg10 mg
1 mM3.6989 mL18.4945 mL36.9891 mL
5 mM0.7398 mL3.6989 mL7.3978 mL
10 mM0.3699 mL1.8495 mL3.6989 mL
50 mM0.0740 mL0.3699 mL0.7398 mL

Description

Tolbutamide (HLS 831) is an inhibitor of , used for type II diabetes.

Targets

Potassium channel [3]

In vitro

Tolbutamide belongs to a class of medications called sulfonylureas. Tolbutamide lowers blood sugar by causing the pancreas to produce insulin (a natural substance that is needed to break down sugar in the body) and helping the body use insulin efficiently. This medication will only help lower blood sugar in people whose bodies produce insulin naturally. Tolbutamide is not used to treat type 1 diabetes (condition in which the body does not produce insulin and, therefore, cannot control the amount of sugar in the blood) or diabetic ketoacidosis (a serious condition that may occur if high blood sugar is not treated). Tolbutamide inhibits both the basal and the cyclic AMP-stimulated protein kinase activities and the IC50 of Tolbutamide is 4 mM. Similar Tolbutamide concentrations are required for half maximal inhibition of in vitro lipolysis induced by hormones (norepinephrine and ACTH) or by dibutyryl cyclic AMP plus theophylline. Tolbutamide also inhibits both soluble and membrane-bound protein kinase from canine heart. The Tolbutamide inhibition of adipose tissue cyclic AMP-dependent protein kinase is one possible explanation for the antilipolytic effects of this drug. Tolbutamide inhibits C6-glioma cell proliferation by increasing Cx43, which correlates with a reduction in pRb phosphorylation due to the up-regulation of the Cdk inhibitors p21 and p27. Cytosolic nucelotides enhance the Tolbutamide sensitivity of the ATP-dependent K+ channel in mouse pancreatic B cells by their combined actions at inhibitory and stimulatory receptors. Tolbutamide inhibits glucagon-induced phosphorylation of the bifunctional enzyme protein in a dose-dependent manner. By adding 2 mM Tolbutamide, reduces activity of 6PF-2-K and increased activity of Fru-2,6-P2ase in the presence of 10(-9) M glucagon are partially restored. The present results suggest the possibility that Tolbutamide modulates the activity of hepatic 6PF-2-K/Fru-2,6-P2ase through inhibiting a phosphorylation of the enzyme protein.

In vivo

450 mg Tolbutamide/kg/day given for 7 days significantly increases the binding of insulin to isolated adipocytes. The binding curves reflect an increase in the number of receptor sites rather than in the affinity. The effect is associated with an enhanced response to insulin of the adipose tissue, since the fat cells obtained from animals treated with Tolbutamide convert significantly more glucose to lipids in the presence of insulin than those obtained from the control group. However, the augmentation of insulin binding sites is observed only at a large tolbutamide dosage, which reduces the pancreatic insulin content, the secretory response of the isolated pancreas, and the serum insulin levels. Smaller doses, sufficient to produce metabolic effects via a stimulation of insulin secretion, do not provide additional insulin binding sites.


Synonyms

Benzenesulfonamide, N-[(butylamino)carbonyl]-4-methyl-
Urea, 1-butyl-3-(p-tolylsulfonyl)-
N-[(Butylamino)carbonyl]-4-methylbenzenesulfonamide
D 860
Artosin
Butamide
1-Butyl-3-(p-methylphenylsulfonyl)urea
N-Butyl-N′-p-toluenesulfonylurea
1-Butyl-3-(p-tolylsulfonyl)urea
N-n-Butyl-N′-tosylurea
Diaben
Diabuton
Dolipol
Ipoglicone
Mobenol
Orabet
Oralin
Orinase
Rastinon
N-(Sulfonyl-p-methylbenzene)-N′-n-butylurea
Tolbutamide
Toluina
N-(p-Tolylsulfonyl)-N′-butylcarbamide
3-(p-Tolyl-4-sulfonyl)-1-butylurea
Diabetol
Butamid
N-(4-Methylphenylsulfonyl)-N′-butylurea
N-(4-Methylbenzenesulfonyl)-N′-butylurea
Tolbutamid
N-Butyl-N′-(p-tolylsulfonyl)urea
N-Butyl-N′-(4-methylphenylsulfonyl)urea
Aglicid
Arkozal
Artozin
Diabetamid
Orezan
Orinaz
Tolumid
Toluvan
Oterben
Tolbusal
Willbutamide
HLS 831
N-(p-Methylbenzenesulfonyl)-N′-butylurea
Tolumide
Pramidex
Diasulfon
Glyconon
U 2043
NSC 23813
NSC 87833
1-Butyl-3-(4-methylphenyl)sulfonylurea
3-Butyl-1-(4-methylbenzenesulfonyl)urea